Trial Profile
A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs T 89 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Tasly Pharmaceuticals, Inc.
- 12 Jun 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Mar 2020 New trial record